Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Guidance, Compliance, & Regulatory Information

Guidance, Compliance, & Regulatory Information

                        Good Review Practices | GRPs


                        Guidances | Drugs
          Electronic Drug Registration and Listing System (eDRLS)
          CDER FOIA Electronic Reading Room
          CDER International Program
          Enforcement Activities | FDA
          Human Drug Compounding
          Human Drug Exports
          Human Drug Imports
          Laws, Acts, and Rules
          Postmarketing Requirements and Commitments: Introduction
          Surveillance: Post Drug-Approval Activities Home
          Drugs
          Guidance, Compliance, & Regulatory Information
          Environmental Impact Statement (EIS) for Certain Sunscreen Drug Products​Guidance, Compliance, & Regulatory Information Environmental Impact Statement (EIS) for Certain Sunscreen Drug Products​
  
  	
    Share
    Post
    Linkedin

    Email
    PrintThe following information relates to FDA’s Environmental Impact Statement (EIS) for Certain Sunscreen Drug Products for over-the-counter (OTC) use.  FDA has published in the Federal Register a notice of intent (NOI) to prepare an EIS under the National Environmental Policy Act (NEPA) to evaluate the potential environmental effects of revised conditions for marketing certain sunscreen products for OTC use without prior approval of a new drug application (NDA). This web page will house information related to the NEPA EIS process.

Before engaging in a major Federal action, NEPA requires federal agencies to consider the potential environmental consequences of proposed actions, and any reasonable alternatives.  Under FDA regulations, FDA will prepare an EIS when data or information in an environmental assessment or otherwise available to the agency leads to a finding that the proposed agency action may significantly affect the quality of the human environment. 1

As explained in the NOI, the Coronavirus Aid, Relief, and Economic Security (CARES) Act, signed into law on March 27, 2020, requires FDA to issue a proposed order addressing sunscreens by September 27, 2021.  FDA expects that the future final sunscreen order will establish revised conditions for marketing a sunscreen product without the prior approval of an NDA, and that among the conditions addressed will be the permissibility of including certain active ingredients in sunscreen products marketed without an NDA.  Because of questions raised about the extent to which two sunscreen active ingredients (oxybenzone and octinoxate) may affect coral and/or coral reefs, FDA is issuing this NOI and initiating the public scoping process to consider any potential environmental impacts associated with the use of oxybenzone and octinoxate in sunscreens so that an EIS, if necessary, can be completed prior to issuance of a final sunscreen order addressing sunscreens containing these ingredients.

The NOI is available in the Federal Register.  If you would like to submit a comment on the NOI, please do so according to the instructions set forth in that document.

FDA will update this webpage periodically.

Additional Information

Proposed administrative order for OTC sunscreen products

	Notice of Availability: Amending Over-the-Counter (OTC) Monograph M020: Sunscreen Drug Products for OTC Human Use1See 21 CFR 25.22(b); 40 CFR 1508.27.

                                                                                  Content current as of:
      10/13/2021
              
              
Regulated Product(s)
		 DrugsGuidance, Compliance, & Regulatory Information

          
                        Good Review Practices | GRPs


                        Guidances | Drugs
          Electronic Drug Registration and Listing System (eDRLS)
          CDER FOIA Electronic Reading Room
          CDER International Program
          Enforcement Activities | FDA
          Human Drug Compounding
          Human Drug Exports
          Human Drug Imports
          Laws, Acts, and Rules
          Postmarketing Requirements and Commitments: Introduction
          Surveillance: Post Drug-Approval Activities
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop